Value Partners Group Limited has led a significant equity investment in PHASE Scientific International Limited, resulting in a US$34 million Series A funding round. This marks the largest Series A raise in Asia's diagnostic technology sector since 2019. The investment aims to accelerate the research and development and commercialization of PHASE Scientific's innovative urine-based diagnostic technology, which targets early detection of multiple cancers, women's health issues, and infectious diseases. Dr. Chuen Yan Leung, Partner at Value Partners Group, expressed confidence in PHASE Scientific's breakthrough technology and its potential to transform early disease detection.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Value Partners Group Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: HK90860) on May 20, 2025, and is solely responsible for the information contained therein.